Back to discover
Disease
Diabetes Complications
Late-stage therapeutic developmentEmerging researchCooling momentum
24
Publications
24
Clinical trials
12
Related conditions
2025
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D
Clinical trial2026-07-28Results posted · ClinicalTrials.gov
ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D
Clinical trial2026-07-28Status changed to Completed · ClinicalTrials.gov
Diabetes Mellitus and Infectious Diseases: Current Evidence and Clinical Implications.
Research2025-08-27Diabetes & metabolism journal
Research2025-01-27International journal of molecular sciences
Tuberculosis and diabetes mellitus: The complexity of the comorbid interactions.
Research2024-06-15International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment.
Research2024-02-20Diabetologia
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema
- Q3 2027A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- Q4 2027A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
- Q4 2027Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
- Q4 2027EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20272026-10-02
Upcoming trial readoutHigh impact
Results expected Q4 20272026-09-08
Clinical MilestonesView all 13Hide
Results posted
Results expected
- 2026-10-02A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)Results expected Q4 2027
- 2026-09-08EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)Results expected Q4 2027
- 2026-08-20A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-04-20A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
- 2026-03-18A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)Results expected Q1 2028
Other updates
- 2029-02-28Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01Phase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01Comparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
+5 more in the activity timeline below
Activity timeline13
- 2029-02-28ClinicalEvaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31ClinicalIntervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01ClinicalA Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01ClinicalPhase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01ClinicalComparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
- 2026-10-02ClinicalA Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)Results expected Q4 2027
- 2026-09-08ClinicalEVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)Results expected Q4 2027
- 2026-08-20ClinicalA Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-06-30ClinicalMetformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes: A Randomized TrialWithdrawn
- 2026-04-20ClinicalA Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
Most influential
Recent publications
Major themes8
- Diabetes Complications7
- Diabetes Mellitus4
- Diabetes Mellitus, Type 22
- Disease Susceptibility2
- Angioplasty, Balloon, Coronary1
- Communicable Diseases1
- Comorbidity1
- Coronary Artery Bypass1
Leading journals6
- Diabetes care3
- International journal of molecular sciences3
- Circulation2
- Endocrine reviews2
- Advanced science (Weinheim, Baden-Wurttemberg, Germany)1
- Biomolecules1
Leading researchers8
- Grundy SM2
- Smith SC Jr2
- Adem A1
- Allen J1
- Anders HJ1
- Anderson RJ1
- Bansilal S1
- Beitelshees AL1
Affiliations (unnormalised)6
- Academic Medical Center1
- Affiliated Hospital of Medical College Qingdao University1
- Ambroise Paré University Hospital1
- Asan Medical Center1
- Centre de Recherche en Épidémiologie et Santé des Populations (CESP)1
- College of Medicine and Health Sciences1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.